Pharmacological activation of Rev-erbα Provides Neuroprotection against Parkinson’s Disease
Objective: In this study, we investigated the effects of SR9009, a Rev-ERB agonist, on the dopaminergic system in the MPTP model of PD. Background: Circadian…Neuroprotective effect of Boswellia dalzielii extracts in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease
Objective: To evaluate the possible protective effects of Boswellia dalzielii in animal model of Parkinson Disease (PD) induced by 6-hydroxydopamine (6-OHDA) injection in the striatum…Protective effects of Hibiscus sabdariffa extracts in 6-hydroxydopamine-lesioned parkinsonism.
Objective: The therapeutic effects of Hibiscus sabdariffa (HS) were investigated in parkinsonism rats induced by 6-hydroxydopamine (6-OHDA). Background: The oxidative stress is an important component…ADS024 attenuates striatal dopamine loss and restores movement in animal models of Parkinson’s disease
Objective: To evaluate the effect of ADS024, an oral single strain live biotherapeutic product (SS-LBP), on the pathophysiology of MPTP-induced Parkinson’s Disease (PD) phenotypes in…A role of β2-adrenoreceptor agonist related to the development of Parkinson’s disease
Objective: To explore β2AR agonist’s effect on PD development with controlling for smoking. Background: Several studies have suggested the potential protective role of β2-adrenoreceptor agonist (β2AR…Neuroprotective effects of Ibudilast, a Phosphodiesterase IV inhibitor in mouse model of Parkinson’s disease
Objective: In the present study, we examined neuroprotective effects, if any, of IBD drug, a inhibitor of the phosphodiesterase IV in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse…Exenatide protects iPSC-derived dopaminergic neurons with A53T mutation through restoration of insulin signaling
Objective: Here we sought to investigate mechanisms by which insulin resistance affects PD pathogenesis in-vitro, and whether restoration of insulin signaling, using GLP-1 agonist exenatide…Effect of CDNF in a novel combination stressor model of Parkinson’s disease
Objective: In this study, our first aim was to develop a model for Parkinson's disease (PD) that would exhibit the alpha-synuclein (αSyn) aggregation pathology and…Effects of a novel neurotrophic compound in an animal model of Parkinson’s disease
Objective: Investigate the neuroprotective effect of a novel compound in an animal model of Parkinson’s disease. Background: Cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte-derived…Tinospora Cordifolia protects against Rotenone induced degeneration of dopaminergic neurons in mouse model of Parkinson’s disease
Objective: To explore the neuroprotective mechanisms of T. cordifolia ethanolic extract against Rotenone (ROT)-intoxicated mouse model through proteomics approach. Background: The death of dopaminergic (DAergic)…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 15
- Next Page »